Back to the Top
The following message was posted to: PharmPK
Hello,
Does anyone can tell me how to do deconvolution for data from IR tablet
with a
solution data (instead of IV data)?
I know how to do it by Wagner-Nelson method but I'd like to know if
someone know
another method to do it without using Kel.
Wagner-Nelson method is relying on Kel and so if you change your Kel,
fraction
absorbed vs. time is changing.
I would very appreciate your input.
Regards,
Hue.
Back to the Top
The following message was posted to: PharmPK
It is interesting to deconvolute an extended released tablet from a
solution
because you can further find a straight relationship with your in vitro
dissolution data. May be you have to adjust the conditions of your in
vitro
dissolution asssay in order to mach the deconvolution but when you find
the
good condition you can simulate your concentration profiles and also
your
effect if you have a PK/PD model too.
I applied this to simulate effect of an extended release cardiovascular
drug
and it was successful.
Dominique Paccaly, Pharm D.
SYNGENOR, Inc
Drug, Metabolism and Pharmacokinetics/US
Tel: 908 240 4970
Back to the Top
The following message was posted to: PharmPK
Dear Dr. Kwon,
You wrote:
> Does anyone can tell me how to do deconvolution for data from IR tablet
> with a solution data (instead of IV data)?
This can be done by numerical deconvolution. Although the procedure is
relatively easy, automated analysis using an adequate computer program
is
recommended. I have written a program, KinBes, for the assessment of
bioavailability and bioequivalence, and, more recently, convolution of
in
vitro dissolution
profiles (input profiles) and unit impulse response data. KinBes
includes
several methods for calculation of bioavailability and drug input
(absorption) profiles, including several methods for numerical
deconvolution. These methods are essentially 'Point-Area' methods as
described by Vaughan and Dennis (J Pharm Sci 1978;67:663-665). I have
made
several modifications to improve the accuracy and precision of the
calculated input profile, which are included in KinBes. This work has
been
the major topic of my PhD thesis in 1987. Despite some criticism in
literature, it is still my opinion that the numerical methods perform
well,
and that the advantage of the more sophisticated methods are not
convincing,
in particular with respect to the accuracy of the cumulative drug input
profile. In addition, the program KinBese includes a variety of methods
for
the assessment of bioequivalence.
The program is commercially available from Mediware. Please contact Mr.
Eddy
van Essen at vanessene.aaa.cs.com.
Best regards,
Johannes H. Proost
Dept. of Pharmacokinetics and Drug Delivery
University Centre for Pharmacy
Antonius Deusinglaan 1
9713 AV Groningen, The Netherlands
tel. 31-50 363 3292
fax 31-50 363 3247
Email: j.h.proost.-a-.farm.rug.nl
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (david@boomer.org)